Hip Resurfacing Implants Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Hip Resurfacing Implants Market Trends and Insights

Rising Preference for Bone-Conserving Arthroplasty in Younger, Active Patients

Hip resurfacing preserves more native bone than total hip arthroplasty, which is important for patients under 55 who may require revision surgery during their lifetime. A 2024 Bone & Joint study found low complication and revision rates among younger male patients with end-stage hip disease who received hip resurfacing arthroplasty. The study also reported a return to high-impact sport without lifetime activity restrictions for suitable patients treated by high-volume surgeons. This clinical profile supports referral to specialist surgeons when functional expectations are high. Ceramic systems with CE marking in 2025 reopened the procedure to women and smaller-framed patients who had been excluded from metal resurfacing for more than 10 years^{[1]NIHR Imperial Biomedical Research Centre, “CE Mark Awarded to Innovative Implant Enabling Hip Resurfacing for Women,” NIHR Imperial Biomedical Research Centre, imperialbrc.nihr.ac.uk}. This broader eligibility changes the potential patient base for the hip resurfacing implants market, especially because women account for 59% of UK hip replacement patients.

Expanding Diagnosis and Surgical Treatment of Hip Osteoarthritis

Global hip osteoarthritis prevalence projected growth in South Asia and East Asia through 2050, with a DALY-rate EAPC of 0.94 in South Asia and an ASPR EAPC of 3.32 in East Asia. A Lancet Rheumatology analysis projected that the global hip osteoarthritis case burden will rise 78.6% between 2020 and 2050^{[2]The Lancet Rheumatology, “Global, Regional, and National Burden of Osteoarthritis, 1990 to 2020 and Projections to 2050,” The Lancet Rheumatology, doi.org}. Population aging and obesity remain central contributors to this clinical burden. Better MRI access and greater clinical awareness can bring younger symptomatic patients to surgical assessment earlier in middle-income countries. This could add demand to the hip resurfacing implants market before it becomes fully visible in recorded procedure volumes.

Adoption of Robotic and Computer-Assisted Component Positioning

Robotic assistance accounted for 6.6% of elective primary total hip arthroplasty procedures in the United States in 2023. NHS Scotland recorded a rise in robotic joint replacements from 101 procedures in 2020 to 1,164 procedures in 2024, showing broader uptake of robotic technology. Hip resurfacing requires precise femoral component alignment, which makes CT-based planning and navigation relevant to procedure quality. Computational planning can improve component positioning compared with manual estimation when narrow alignment tolerances are required. The use of these tools also supports cementless designs that need consistent bone preparation. Their wider availability can make the hip resurfacing implants market more accessible to centers that are building specialist arthroplasty capabilities.

Ceramic and Low-Wear Bearing Innovation Expanding Patient Eligibility

Ceramic bearing systems are changing treatment access because they avoid the metal exposure concerns associated with metal-on-metal designs. The H1 ceramic-on-ceramic implant received CE marking under the EU Medical Device Regulation in July 2025 as the first non-metal hip resurfacing implant approved globally. Its cementless design is intended for women and patients with smaller femoral head anatomy. The German hip registry reported ceramic head material use in 90% of primary total hip arthroplasties in Germany, indicating established clinician familiarity with ceramic materials. EU MDR requirements for postmarket clinical follow-up and EUDAMED registration favor companies that can demonstrate validated clinical outcomes. These requirements can extend the lead of early ceramic entrants in the hip resurfacing implants market before additional regulatory submissions begin.

Metal-Ion Release, Pseudotumor, and Adverse Local Tissue Reaction Concerns

Adverse local tissue reactions, pseudotumors, and systemic cobalt-chromium ion accumulation remain significant concerns with metal-on-metal hip resurfacing. These safety issues affect adoption volumes and pricing power for suppliers of metal-on-metal systems. The FDA continues to review postmarket surveillance and Medical Device Reports for metal-on-metal hip implants. It also maintains 522 postmarket study orders that require ongoing manufacturer safety evidence. Earlier device safety events remain influential in hospital procurement decisions, including for systems with stronger supporting evidence. This institutional caution slows referrals and leaves ceramic suppliers in the hip resurfacing implants market dependent on registry data and surgeon education to build confidence.

Regulatory Scrutiny, Litigation, and Product-Recall Risk

Regulatory scrutiny is increasing compliance costs and extending commercialization timelines, especially for smaller device innovators. The FDA recorded a Class 2 recall for Smith & Nephew’s Oxinium hip component in April 2024 because of labeling discrepancies. Zimmer Biomet voluntarily recalled its CPT Hip System Femoral Stem in July 2024 after identifying elevated periprosthetic femoral fracture risk. EU MDR requires more clinical evidence, ongoing surveillance, and EUDAMED registration than the prior European framework. For hip resurfacing, long-term survival evidence across diverse patient populations can require 5 to 10 years of registry follow-up before authorization or renewal. This raises barriers to entry in the hip resurfacing implants market and favors established companies with robust clinical datasets.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Ceramic Bearings Challenge Metal-on-Metal Incumbency

Metal-on-metal implants held 39.31% of the Hip resurfacing implants market share in 2025, supported by an installed base and surgeon familiarity with Birmingham Hip Resurfacing format procedures. Ceramic-on-ceramic implants are the fastest-growing product type and are projected to record a 7.85% CAGR from 2026 to 2031. Smith & Nephew discontinued Birmingham Hip Resurfacing manufacturing in 2024 after annual sales declined from USD 100 million to USD 9 million. The withdrawal is moving procedure volumes toward ceramic and hybrid alternatives. Metal-on-polyethylene configurations retain relevance as lower-cost options with established safety profiles in public procurement environments.

Hybrid and other configurations serve patients whose anatomy or clinical needs are not optimally addressed by full ceramic or metal-on-metal designs. The hip resurfacing implants market size for ceramic-on-ceramic products is expected to expand at a 7.85% CAGR from 2026 to 2031. ReCerf received approvals in Australia in November 2024 and the EU in July 2025, while later Canadian approval extended its commercial footprint. Its 5A* ODEP rating, awarded in May 2026, supports assessment by NHS and European hospital procurement groups. Zimmer Biomet’s exclusive H1 licensing arrangement with Embody Orthopedic adds distribution capability to the hip resurfacing implants market for ceramic resurfacing.

By Material and Bearing Couple: CoCr Dominance Contested by Advanced Ceramics

Cobalt-chromium alloy held 41.24% of the material and bearing couple segment in 2025. Its position reflected the legacy base of metal-on-metal systems and continued use in hybrid fixation designs. Titanium alloy remained important in acetabular shells and cementless femoral components, where biological fixation is the design objective. Highly cross-linked polyethylene supports metal-on-polyethylene and ceramic-on-polyethylene options. Ceramic-on-metal and other niche combinations address narrower clinical requirements.

Alumina and zirconia-toughened ceramics are forecast to grow at a 7.22% CAGR from 2026 to 2031, making them the fastest-growing material category. CeramTec supplies ceramic materials to MatOrtho and Zimmer Biomet, creating a common material base for 2 advanced ceramic programs. A 2025 Lubrication Science study reported negligible wear for BIOLOX delta ceramic-on-ceramic resurfacing under walking and jogging loads. ISO 6474 governs performance standards for alumina-based implant ceramics in major markets. A concentrated supply of ceramic blanks could constrain volume scaling in the hip resurfacing implants market if demand grows faster than production capacity.

By Fixation Type: Cementless Designs Gain Momentum Across Both Components

Cementless femoral component fixation held 44.14% of the hip resurfacing implants market share in 2025. The share reflected interest in biological fixation for younger, active patients. Cementless acetabular component fixation is the fastest-growing approach, with an 8.42% CAGR projected from 2026 to 2031. Fully cementless systems are replacing the older hybrid model that used a cemented femoral cap and press-fit acetabular cup. Zimmer Biomet’s H1 system and MatOrtho’s ReCerf illustrate this direction^{[3]Zimmer Biomet, “H1 Hip Resurfacing Product Brochure 2026,” Zimmer Biomet, downloads.ctfassets.net}.

The hip resurfacing implants market size for cementless acetabular fixation is projected to grow at an 8.42% CAGR through 2031. Cemented femoral and hybrid fixation remain relevant where bone quality or procedural familiarity is decisive. Cementless femoral resurfacing requires precise bone preparation and tolerance control during surgery. This requirement increases the value of navigation and robotic planning tools. Purpose-built cementless instrumentation can give manufacturers a meaningful competitive advantage.

By Indication: Primary Osteoarthritis Anchors Volume, Hip Dysplasia Drives Emerging Demand

Primary osteoarthritis held 61.14% of the indication segment in 2025 and remained the main reason for hip resurfacing referral. The World Health Organization identifies hip and knee joints as osteoarthritis sites where surgery can be effective. Rising osteoarthritis prevalence supports stable procedural demand in North America and Europe. Rheumatoid arthritis, avascular necrosis, and post-traumatic arthritis also generate specialist demand. These cases require assessment because anatomy and disease progression differ from primary osteoarthritis.

Hip dysplasia is projected to grow at a 7.12% CAGR from 2026 to 2031. Ceramic implants with anatomically contoured designs can better accommodate dysplastic acetabular geometry than older metal systems. A 2024 Journal of Arthroplasty report on the first 200 ceramic-on-ceramic procedures found improved Oxford Hip Score, HOOS, and WOMAC results. It also documented 53% return to impact activity at 2 years and cited 96.3% survival at 8 years in follow-up cohort data. This evidence may support broader future guidance for dysplasia patients in the hip resurfacing implants market.

By End User: Hospitals Maintain Procedural Lead, ASCs Represent the Growth Vector

Hospitals accounted for 54.61% of end-user revenue in 2025. Their lead reflected the need for imaging, experienced teams, and capital equipment in robotic cases. Ambulatory surgical centers are the fastest-growing end-user category, with an 8.25% CAGR forecast from 2026 to 2031. The analysis provided that 62,110 total joint procedures were performed at ambulatory surgical centers in 2023, a 70% year-over-year increase.

The hip resurfacing implants market size for ambulatory surgical centers is forecast to advance at an 8.25% CAGR through 2031. Orthopedic clinics retain a secondary specialist role in decentralized care systems. Academic medical centers and private surgical hospitals concentrate high-volume resurfacing activity in the UK, Germany, and Australia. These settings also support many surgeon training programs. Better ceramic systems and instrumentation can allow ambulatory surgical centers to capture more Hip resurfacing implant procedures while hospitals retain complex cases.

Geography Analysis

North America held 42.41% of the global hip resurfacing implants share in 2025. The region remains the largest because of advanced orthopedic practice, reimbursement for specialist devices, and early navigation adoption. Canada gained a path for all-ceramic resurfacing when ReCerf received Health Canada approval in July 2026, while a public cost-effectiveness review will influence adoption. Mexico remains at an early stage, with procedures concentrated in private hospital groups in major cities.

Germany maintained a large procedural base with 199,052 primary hip implantations and 19,656 revision procedures in 2024. Its mandatory EPRD registry gives new ceramic systems an established route to commercial validation. ReCerf was first implanted in Germany in September 2025. Cleveland Clinic London performed an early H1 ceramic procedure in October 2025 after MHRA approval. EU MDR requirements are increasing the importance of clinical evidence across France, Italy, and Spain.

Asia-Pacific is the fastest-growing region in the hip resurfacing implants market, with an 8.05% CAGR projected from 2026 to 2031. Growth is supported by demographic demand, healthcare investment, and expanding private surgical infrastructure. Japan has high robotic adoption, while South Korea supports domestic and international ceramic designs through its regulatory pathways. Australia granted the first regulatory approval for an all-ceramic system in November 2024. China’s centralized purchasing policies reduce implant prices and place pressure on margins. Private tertiary hospitals in GCC countries, private insurance growth, and surgeon training in Brazil and Argentina are broadening access elsewhere.